Histone deacetylases (HDACs) are master regulators of chromatin remodeling, acting as epigenetic regulators of gene expression. In the last decade, inhibition of HDACs has become a target for specific epigenetic modifications related to cancer development. Overexpression of HDAC has been observed in several hematologic malignancies. Therefore, the observation that HDACs might play a role in various hematologic malignancies has brought to the development of HDAC inhibitors as potential antitumor agents. Recently, the class IIb, HDAC6, has emerged as one potential selective HDACi. This isoenzyme represents an important pharmacological target for selective inhibition. Its selectivity may reduce the toxicity related to the off-target effects of pan-HDAC inhibitors. HDAC6 has also been studied in cancer especially for its ability to coordinate a variety of cellular processes that are important for cancer pathogenesis. HDAC6 has been reported to be overexpressed in lymphoid cells and its inhibition has demonstrated activity in preclinical and clinical study of lymphoproliferative disease. Various studies of HDAC6 inhibitors alone and in combination with other agents provide strong scientific rationale for the evaluation of these new agents in the clinical setting of hematological malignancies. In this review, we describe the HDACs, their inhibitors, and the recent advances of HDAC6 inhibitors, their mechanisms of action and role in lymphoproliferative disorders.
The therapeutic strategy of HDAC6 inhibitors in lymphoproliferative disease / Cosenza, M.; Pozzi, S.. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1661-6596. - 19:8(2018), pp. 2337-2337.
|Data di pubblicazione:||2018|
|Titolo:||The therapeutic strategy of HDAC6 inhibitors in lymphoproliferative disease|
|Autore/i:||Cosenza, M.; Pozzi, S.|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.3390/ijms19082337|
|Codice identificativo ISI:||WOS:000442869800189|
|Codice identificativo Scopus:||2-s2.0-85052121049|
|Codice identificativo Pubmed:||30096875|
|Citazione:||The therapeutic strategy of HDAC6 inhibitors in lymphoproliferative disease / Cosenza, M.; Pozzi, S.. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1661-6596. - 19:8(2018), pp. 2337-2337.|
|Tipologia||Articolo su rivista|
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris